share_log

11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

11-K: Annual report of employee stock purchase, savings and similar plans (and amendment thereto)

11-K:員工持股年度報告
美股SEC公告 ·  06/21 10:40
Moomoo AI 已提取核心訊息
Novo Nordisk A/S, a global healthcare company, has filed its annual Form 11-K report with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2023. The report includes audited financial statements for the Novo Nordisk Inc. 401(k) Savings Plan, which is a defined contribution plan for U.S. employees. The independent auditor, EisnerAmper LLP, has expressed an unqualified opinion that the financial statements present fairly the net assets available for benefits and the changes therein for the years ended December 31, 2023, and 2022. The Plan's net assets available for benefits increased significantly from $1,769,202,694 in 2022 to $2,303,296,181 in 2023. The Plan offers a variety of investment options, including mutual funds, common stock, and common collective trusts, with the fair value...Show More
Novo Nordisk A/S, a global healthcare company, has filed its annual Form 11-K report with the U.S. Securities and Exchange Commission for the fiscal year ended December 31, 2023. The report includes audited financial statements for the Novo Nordisk Inc. 401(k) Savings Plan, which is a defined contribution plan for U.S. employees. The independent auditor, EisnerAmper LLP, has expressed an unqualified opinion that the financial statements present fairly the net assets available for benefits and the changes therein for the years ended December 31, 2023, and 2022. The Plan's net assets available for benefits increased significantly from $1,769,202,694 in 2022 to $2,303,296,181 in 2023. The Plan offers a variety of investment options, including mutual funds, common stock, and common collective trusts, with the fair value of investments in Novo Nordisk A/S common stock reported at $540,264,197 as of December 31, 2023. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA) and is designed to be in compliance with the Internal Revenue Code. The Plan's investments are subject to market risks and uncertainties, which could materially affect account balances and the values of net assets available for benefits.
全球醫療保健公司諾和諾德已向美國證券交易所提交了截止於2023年12月31日的年度11-K表格報告。該報告包括諾和諾德401(k)儲蓄計劃的審計基本報表,該計劃是爲美國員工設計的一項確定性繳款計劃。獨立核數師EisnerAmper LLP已經表示財務報表公正地呈現出2023年和2022年的可用福利淨資產和變動情況。該計劃的可用福利淨資產從2022年的1,769,202,694美元大幅增加至2023年的2,303,296,181美元。該計劃提供多種投資選擇,包括共同基金、普通股票和共同信託基金,截至2023年12月31日,諾和諾德A/S普通股票投資的公允價值報告爲5,402,641,197美元。該計劃受僱員退休收入保障法案的規定約束,並設計爲符合內部收入法典的規定。該計劃的投資受市場風險和不確定性的影響,這可能會對帳户餘額和可用福利淨資產的價值造成重大影響。
全球醫療保健公司諾和諾德已向美國證券交易所提交了截止於2023年12月31日的年度11-K表格報告。該報告包括諾和諾德401(k)儲蓄計劃的審計基本報表,該計劃是爲美國員工設計的一項確定性繳款計劃。獨立核數師EisnerAmper LLP已經表示財務報表公正地呈現出2023年和2022年的可用福利淨資產和變動情況。該計劃的可用福利淨資產從2022年的1,769,202,694美元大幅增加至2023年的2,303,296,181美元。該計劃提供多種投資選擇,包括共同基金、普通股票和共同信託基金,截至2023年12月31日,諾和諾德A/S普通股票投資的公允價值報告爲5,402,641,197美元。該計劃受僱員退休收入保障法案的規定約束,並設計爲符合內部收入法典的規定。該計劃的投資受市場風險和不確定性的影響,這可能會對帳户餘額和可用福利淨資產的價值造成重大影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息